Compare Biogen Inc (BIIB) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs FedEx Corporation — how do they compare? Biogen Inc trades at $191.2 (market cap $28.34B), while FedEx Corporation trades at $318.19 (market cap $74.84B). The key difference: FedEx Corporation is far larger — about 2.6× Biogen Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | FDX | |
|---|---|---|
Market Cap | $28.34B | $74.84B |
Sector | Health | Industrials |
52-Week High | $216.63 | $338.75 |
52-Week Low | $122.68 | $174.81 |
Enterprise Value | $30.62B | $104.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
FedEx (FDX) trades at $313.74, down 0.3% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $6.31, beating expectations, and is executing strategic moves like the $1.4 billion sale of its supply chain unit to CMA CGM. Valuation ratios appear reasonable with a P/E of 16.91 and P/S of 0.79, while analyst consensus remains positive with a $358.80 price target.
The outlook is mixed; cost-cutting initiatives and debt reduction via a $4.15 billion tender offer support fundamentals, but weak shipping demand and margin pressures pose risks. Upside depends on margin recovery from DRIVE and Network 2.0 programs, though competitive threats from Amazon logistics and economic sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
